275 related articles for article (PubMed ID: 36000426)
1. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
[TBL] [Abstract][Full Text] [Related]
2. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
3. Association between early worsening of kidney function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis.
Yuan S; Liu Y; He W; Jin J; Liu L; He Q
Nephrology (Carlton); 2021 Oct; 26(10):772-781. PubMed ID: 34165226
[TBL] [Abstract][Full Text] [Related]
4. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
Bangalore S; Fakheri R; Wandel S; Toklu B; Wandel J; Messerli FH
BMJ; 2017 Jan; 356():j4. PubMed ID: 28104622
[TBL] [Abstract][Full Text] [Related]
5. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Lee MMY; Kondo T; Campbell RT; Petrie MC; Sattar N; Solomon SD; Vaduganathan M; Jhund PS; McMurray JJV
Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):68-80. PubMed ID: 37740450
[TBL] [Abstract][Full Text] [Related]
7. Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial).
Legrand M; Futier E; Leone M; Deniau B; Mebazaa A; Plaud B; Coriat P; Rossignol P; Vicaut E; Gayat E;
Trials; 2019 Mar; 20(1):160. PubMed ID: 30836981
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
[TBL] [Abstract][Full Text] [Related]
10. Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension.
Gnanenthiran SR; Borghi C; Burger D; Charchar F; Poulter NR; Schlaich MP; Steckelings UM; Stergiou G; Tomaszewski M; Unger T; Wainford RD; Williams B; Rodgers A; Schutte AE
BMJ Open; 2021 Feb; 11(2):e043625. PubMed ID: 33593784
[TBL] [Abstract][Full Text] [Related]
11. Beta-blockers for hypertension.
Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
[TBL] [Abstract][Full Text] [Related]
12. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
Yin J; Wang C; Song X; Li X; Miao M
Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
[TBL] [Abstract][Full Text] [Related]
14. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
[TBL] [Abstract][Full Text] [Related]
15. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
16. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Cohen JB; Hanff TC; William P; Sweitzer N; Rosado-Santander NR; Medina C; Rodriguez-Mori JE; Renna N; Chang TI; Corrales-Medina V; Andrade-Villanueva JF; Barbagelata A; Cristodulo-Cortez R; Díaz-Cucho OA; Spaak J; Alfonso CE; Valdivia-Vega R; Villavicencio-Carranza M; Ayala-García RJ; Castro-Callirgos CA; González-Hernández LA; Bernales-Salas EF; Coacalla-Guerra JC; Salinas-Herrera CD; Nicolosi L; Basconcel M; Byrd JB; Sharkoski T; Bendezú-Huasasquiche LE; Chittams J; Edmonston DL; Vasquez CR; Chirinos JA
Lancet Respir Med; 2021 Mar; 9(3):275-284. PubMed ID: 33422263
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.
Meza N; Pérez-Bracchiglione J; Pérez I; Carvajal C; Ortiz-Muñoz L; Olguín P; Rada G; Madrid E;
Medwave; 2021 Mar; 21(2):e8105. PubMed ID: 33830976
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Salvador GL; Marmentini VM; Cosmo WR; Junior EL
Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19.
Palazzuoli A; Tecson KM; Vicenzi M; D'Ascenzo F; De Ferrari GM; Monticone S; Secco GG; Tavazzi G; Forleo G; Severino P; Fedele F; De Rosa F; McCullough PA
Am J Cardiol; 2022 Mar; 167():133-138. PubMed ID: 35027137
[TBL] [Abstract][Full Text] [Related]
20. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
